A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis
Muscle & Nerve · 2025-01 · 71 (1) · 63-72
DOI: 10.1002/mus.28287 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, online erschienen am 07.11.2024. Verfasst von Salman Bhai und 26 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Memantine, Amyotrophic Lateral Sclerosis, Disease Progression. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA HHS, FDA-OPD, U.S. Food and Drug Administration.
Abstract (Originalsprache)
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no known cure, limited treatment options with minimal benefits, and significant unmet need for disease modifying therapies.
Aims
This study investigated memantine's impact on ALS progression, with an additional focus on the effects of memantine on cognitive and behavioral changes associated with the disease.
Methods
A randomized, double‐blind, placebo‐controlled clinical trial was conducted from December 2018 to September 2020. ALS patients were enrolled in‐person and remotely across 13 sites in the United States. Participants were randomized to memantine (20 mg twice daily) or placebo in a 2:1 ratio and completed 36 weeks of treatment. The primary outcome of disease progression was assessed by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS‐R), and blood was collected for biomarker analysis.
Results
Of the 99 participants enrolled in the study, 89 were randomized to memantine or placebo (ages 24–83 years, male‐to‐female ratio ~3:2). Fifty‐two participants completed the study treatment with no significant differences in disease progression, biomarker changes (including neurofilament light chain [NfL]), or neuropsychiatric testing noted between the groups. Initial NfL values correlated with the rate of ALSFRS‐R decline.
Discussion
In this study, memantine did not impact ALS disease progression or neuropsychiatric symptoms. Trials with remote enrollment may help trial participation and success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Neuromuscular Center, Institute for Exercise and Environmental Medicine, Texas Health Dallas, Dallas, Texas, USA.
- Honor Health, Scottsdale, Arizona, USA.
- Calico Consulting, Livermore, California, USA.
- Barrow Neurological Institute, Phoenix, Arizona, USA.
- University of Kansas Medical Center, Kansas City, Kansas, USA.
ORCID-Profile: Salman Bhai, Andrew J Heim, Zachary Simmons, Tiffany Schwasinger-Schmidt, Michael Weiss, Jeffrey Statland
Förderung
- FDA HHS
- FDA-OPD
- U.S. Food and Drug Administration
Zitieren
APA
Bhai, S., Levine, T., Moore, D., Bowser, R., Heim, A. J., Walsh, M., Shibani, A., Simmons, Z., Grogan, J., Goyal, N. A., Govindarajan, R., Hussain, Y., Papsdorf, T., Schwasinger-Schmidt, T., Olney, N., Goslin, K., Pulley, M., Kasarskis, E., Weiss, M., …, & Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group (2025). A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis. Muscle & Nerve, 71(1), 63-72. https://doi.org/10.1002/mus.28287
Vancouver
Bhai S, Levine T, Moore D, Bowser R, Heim AJ, Walsh M, et al. A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis. Muscle & Nerve. 2025;71(1):63-72. doi:10.1002/mus.28287
BibTeX
@article{Bhai2025,
author = {Bhai, Salman and Levine, Todd and Moore, Dan and Bowser, Robert and Heim, Andrew J and Walsh, Maureen and Shibani, Aziz and Simmons, Zachary and Grogan, James and Goyal, Namita A and Govindarajan, Raghav and Hussain, Yessar and Papsdorf, Tania and Schwasinger-Schmidt, Tiffany and Olney, Nick and Goslin, Kim and Pulley, Michael and Kasarskis, Edward and Weiss, Michael and Katz, Susan W and Moser, Suzan and Jabari, Duaa and Jawdat, Omar and Statland, Jeffrey and Dimachkie, Mazen M and Barohn, Richard and Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group, Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group},
title = {A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis},
journal = {Muscle & Nerve},
year = {2025},
volume = {71},
number = {1},
pages = {63--72},
doi = {10.1002/mus.28287}
}
EUVIMED